prazosin has been researched along with Cancer of Prostate in 36 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study reviews and assesses the safety of terazosin for the treatment of symptomatic benign prostatic hyperplasia (BPH)." | 9.07 | Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. ( Lowe, FC, 1994) |
| "3H-Doxazosin binding sites were characterized in canine brain and human prostate homogenates using saturation experiments." | 5.28 | Binding and functional properties of doxazosin in the human prostate adenoma and canine brain. ( Baumann, M; Lepor, H; Shapiro, E, 1990) |
| "This study reviews and assesses the safety of terazosin for the treatment of symptomatic benign prostatic hyperplasia (BPH)." | 5.07 | Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. ( Lowe, FC, 1994) |
| " For bladder cancer cell lines used here such as 253J, 5637, KK-47, T24 and UM-UC-3 cells, prazosin, a selective α(1)-adrenoceptor blocker, reduced cell viability at concentrations more than 30 µmol/l." | 3.78 | Antitumor action of α(1)-adrenoceptor blockers on human bladder, prostate and renal cancer cells. ( Gotoh, A; Kanno, T; Nagaya, H; Nishizaki, T, 2012) |
| "A total of 34 men with benign prostatic hyperplasia (BPH) who have been on terazosin treatment (for the obstructive symptoms) were pathologically diagnosed with prostate cancer following surgery." | 3.71 | Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. ( Borkowski, A; Isaacs, JT; Jacobs, SC; Keledjian, K; Kim, G; Kyprianou, N, 2001) |
| "The adrenergic alpha-1 and -2 adrenoceptors in six human hypertrophied prostatic adenomas were measured in the saturation experiment using 3H-prazosin and 3H-yohimbine." | 3.68 | [Comparison of selective alpha-1 blockades for alpha-receptors in human hypertrophied prostatic adenomas]. ( Kondo, S; Morita, T, 1992) |
| "The adrenergic alpha-1 and -2 adrenoceptors in human hypertrophied and non-hypertrophied prostatic adenomas were measured in the saturation experiment using 3H-prazosin and 3H-yohimbine." | 3.68 | [Quantitative analyses of human prostatic alpha-adrenoceptors and effects of terazosin on the alpha-adrenoceptor activity]. ( Morita, T, 1991) |
| "The effect of prazosin on the adrenergic receptors in the human prostatic adenoma and prostatic capsule was investigated by an in vitro isometric technique." | 3.66 | The alpha-adrenergic blocking effect of prazosin on the human prostate. ( Caine, M; Mazouz, B; Shapiro, A, 1981) |
| "Patients with prostate cancer are initially treated with surgical resection, radiation or antiandrogen therapy." | 2.42 | The role of alpha-blockers in the management of prostate cancer. ( Kyprianou, N; Rowland, RG; Tahmatzopoulos, A, 2004) |
| "Treatment with prazosin (30 μM) altered the expression of several cell stress-related proteins: elevating phospho-p38α and reducing S6 kinase in both cell lines." | 1.43 | Relative cytotoxic potencies and cell death mechanisms of α1 -adrenoceptor antagonists in prostate cancer cell lines. ( Anoopkumar-Dukie, S; Chess-Williams, R; Forbes, A; McDermott, C, 2016) |
| "Terazosin or genistein treatment inhibited the growth of DU-145 cells in a dose-dependent manner, whereas had no effect on normal prostate epithelial cells." | 1.35 | Combined effects of terazosin and genistein on a metastatic, hormone-independent human prostate cancer cell line. ( Chang, KL; Cheng, HL; Chih, TT; Hsieh, BS; Hu, YC; Huang, LW; Shyu, HW; Su, SJ, 2009) |
| "All newly diagnosed prostate cancer cases unexposed to alpha1-adrenoreceptor antagonists in the total male Veterans Affairs population during this period were also identified from the Kentucky Cancer Registry database." | 1.34 | Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. ( Baron, AT; Becker, A; Conner, W; Durbin, EB; Harris, AM; Kimbler, K; Kyprianou, N; Lane, M; Rowland, RG; Warner, BW; Wilson, JM, 2007) |
| "Androgen independent PC-3 prostate cancer cells and PC-3 transfectant clones over expressing the apoptosis suppressor bcl-2 were used as an in vitro model." | 1.32 | Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2. ( Keledjian, K; Kyprianou, N, 2003) |
| "Here, by using two human prostate cancer epithelial (hPCE) cell models - primary cells from resection specimens (primary hPCE cells) and an LNCaP (lymph node carcinoma of the prostate) cell line - we identify an alpha1A subtype of adrenergic receptor (alpha1A-AR) and show its functional coupling to plasmalemmal cationic channels via direct diacylglycerol (DAG) gating." | 1.32 | Alpha1-adrenergic receptors activate Ca(2+)-permeable cationic channels in prostate cancer epithelial cells. ( Bonnal, JL; Dewailly, E; Lemonnier, L; Mauroy, B; Prevarskaya, N; Roudbaraki, M; Shuba, Y; Skryma, R; Slomianny, C; Sydorenko, V; Thebault, S, 2003) |
| "Men participating in the 2001 and 2002 Prostate Cancer Awareness Week screening for prostate cancer were given a self-administered questionnaire." | 1.32 | Herbal and vitamin supplement use in a prostate cancer screening population. ( Barqawi, A; Crawford, ED; Gamito, E; O'Donnell, C, 2004) |
| "Our results indicate that treatment of prostate cancer cells with doxazosin or terazosin results in a significant loss of cell viability, via induction of apoptosis in a dose-dependent manner, whereas tamsulosin had no effect on prostate cell growth." | 1.31 | Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. ( Benning, CM; Kyprianou, N, 2000) |
| "Benign prostate hyperplasia (BPH) and prostate cancer established that disruption of the molecular mechanisms that regulate apoptosis and cell proliferation among the stromal and epithelial cell populations, may underlie the neoplastic development that characterizes the aging gland." | 1.31 | Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease. ( Benning, CM; Chon, J; Kyprianou, N, 2000) |
| "5." | 1.29 | Alfuzosin, a selective alpha 1-adrenoceptor antagonist in the lower urinary tract. ( Gautier, E; Hicks, PE; Langer, SZ; Lechaire, J; Lefèvre-Borg, F; Manoury, P; O'Connor, SE; Pierre, F; Pimoule, C; Schoemaker, H, 1993) |
| "3H-Doxazosin binding sites were characterized in canine brain and human prostate homogenates using saturation experiments." | 1.28 | Binding and functional properties of doxazosin in the human prostate adenoma and canine brain. ( Baumann, M; Lepor, H; Shapiro, E, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.56) | 18.7374 |
| 1990's | 11 (30.56) | 18.2507 |
| 2000's | 17 (47.22) | 29.6817 |
| 2010's | 6 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antonello, A | 1 |
| Hrelia, P | 1 |
| Leonardi, A | 1 |
| Marucci, G | 1 |
| Rosini, M | 2 |
| Tarozzi, A | 2 |
| Tumiatti, V | 1 |
| Melchiorre, C | 1 |
| Maestri, V | 1 |
| Simoni, E | 1 |
| Cilia, A | 1 |
| Poggesi, E | 1 |
| Naldi, M | 1 |
| Nicolini, B | 1 |
| Pruccoli, L | 1 |
| Minarini, A | 1 |
| Cain, DT | 1 |
| Battersby, I | 1 |
| Doyle, R | 1 |
| Forbes, A | 2 |
| Anoopkumar-Dukie, S | 2 |
| Chess-Williams, R | 2 |
| McDermott, C | 1 |
| Batty, M | 1 |
| Pugh, R | 1 |
| Rathinam, I | 1 |
| Simmonds, J | 1 |
| Walker, E | 1 |
| McDermott, CM | 1 |
| Spencer, B | 1 |
| Christie, D | 1 |
| Chang, KL | 1 |
| Cheng, HL | 1 |
| Huang, LW | 1 |
| Hsieh, BS | 1 |
| Hu, YC | 1 |
| Chih, TT | 1 |
| Shyu, HW | 1 |
| Su, SJ | 1 |
| Friedman, GD | 1 |
| Udaltsova, N | 1 |
| Habel, LA | 1 |
| Gotoh, A | 1 |
| Nagaya, H | 1 |
| Kanno, T | 1 |
| Nishizaki, T | 1 |
| Merrick, GS | 1 |
| Butler, WM | 1 |
| Wallner, KE | 1 |
| Lief, JH | 1 |
| Galbreath, RW | 1 |
| Pan, SL | 1 |
| Guh, JH | 2 |
| Huang, YW | 1 |
| Chern, JW | 1 |
| Chou, JY | 1 |
| Teng, CM | 1 |
| Keledjian, K | 2 |
| Kyprianou, N | 8 |
| Thebault, S | 1 |
| Roudbaraki, M | 1 |
| Sydorenko, V | 1 |
| Shuba, Y | 1 |
| Lemonnier, L | 1 |
| Slomianny, C | 1 |
| Dewailly, E | 1 |
| Bonnal, JL | 1 |
| Mauroy, B | 1 |
| Skryma, R | 1 |
| Prevarskaya, N | 1 |
| Xu, K | 1 |
| Wang, X | 1 |
| Ling, M | 1 |
| Wong, Y | 1 |
| Barqawi, A | 1 |
| Gamito, E | 1 |
| O'Donnell, C | 1 |
| Crawford, ED | 1 |
| Tahmatzopoulos, A | 2 |
| Rowland, RG | 2 |
| Liu, SJ | 1 |
| Xu, KX | 1 |
| Wang, XF | 1 |
| Hou, SK | 1 |
| Wang, YC | 1 |
| Harris, AM | 1 |
| Warner, BW | 1 |
| Wilson, JM | 1 |
| Becker, A | 1 |
| Conner, W | 1 |
| Lane, M | 1 |
| Kimbler, K | 1 |
| Durbin, EB | 1 |
| Baron, AT | 1 |
| Lin, SC | 1 |
| Chueh, SC | 1 |
| Hsiao, CJ | 1 |
| Li, TK | 1 |
| Chen, TH | 1 |
| Liao, CH | 1 |
| Lyu, PC | 1 |
| Shapiro, A | 1 |
| Mazouz, B | 1 |
| Caine, M | 1 |
| Konen, JC | 1 |
| Lowe, FC | 1 |
| Lefèvre-Borg, F | 1 |
| O'Connor, SE | 1 |
| Schoemaker, H | 1 |
| Hicks, PE | 1 |
| Lechaire, J | 1 |
| Gautier, E | 1 |
| Pierre, F | 1 |
| Pimoule, C | 2 |
| Manoury, P | 1 |
| Langer, SZ | 2 |
| Faure, C | 1 |
| Vallancien, G | 1 |
| Graham, D | 1 |
| Kobayashi, S | 1 |
| Tang, R | 1 |
| Shapiro, E | 2 |
| Lepor, H | 2 |
| Wu, Y | 1 |
| Kawabe, K | 1 |
| Zelefsky, MJ | 1 |
| Ginor, RX | 1 |
| Fuks, Z | 1 |
| Leibel, SA | 1 |
| Benning, CM | 3 |
| Chon, J | 1 |
| Borkowski, A | 1 |
| Kim, G | 1 |
| Isaacs, JT | 1 |
| Jacobs, SC | 1 |
| Kaczmarek, A | 1 |
| Kasprzak, J | 1 |
| Morita, T | 2 |
| Kondo, S | 1 |
| Baumann, M | 1 |
| Alver, JE | 1 |
| Mooppan, UM | 1 |
| Kester, RR | 1 |
| Gintautas, J | 1 |
| Abadir, AR | 1 |
| Kim, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Open-Labeled Study of Prophylactic Vs. Therapeutic Use of Uroxatrol to Determine Improvements in Urinary Morbidity Following Men Undergoing Prostate Brachytherapy[NCT00201630] | Phase 3 | 150 participants | Interventional | 2005-09-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for prazosin and Cancer of Prostate
| Article | Year |
|---|---|
The Role of α1-Adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Antineoplastic Agents; Doxazosin; Female; Humans; | 2016 |
Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; | 2004 |
The role of alpha-blockers in the management of prostate cancer.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Angiogenesis Inhibitors; Anoi | 2004 |
2 trials available for prazosin and Cancer of Prostate
| Article | Year |
|---|---|
Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Biopsy; Brachytherapy; Doxazosin; Follow-Up Studies; H | 2002 |
Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind M | 1994 |
31 other studies available for prazosin and Cancer of Prostate
| Article | Year |
|---|---|
Design, synthesis, and biological evaluation of prazosin-related derivatives as multipotent compounds.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antioxidants; Bioche | 2005 |
Quinazoline based α
Topics: Adrenergic alpha-1 Receptor Antagonists; Apoptosis; Cell Proliferation; Dose-Response Relationship, | 2017 |
Response of dogs with urinary tract obstructions secondary to prostatic carcinomas to the α-1 antagonist prazosin.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Carcinoma; Dog Diseases; Dogs; Male; Prazosin; Pro | 2016 |
Relative cytotoxic potencies and cell death mechanisms of α1 -adrenoceptor antagonists in prostate cancer cell lines.
Topics: Adrenergic alpha-1 Receptor Antagonists; Antineoplastic Agents; Apoptosis; Autophagy; Cell Death; Ce | 2016 |
Combined effects of terazosin and genistein on a metastatic, hormone-independent human prostate cancer cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell | 2009 |
Norepinephrine antagonists and cancer risk.
Topics: Atenolol; Breast Neoplasms; Clonidine; Colonic Neoplasms; Female; Humans; Lung Neoplasms; Male; Meto | 2011 |
Antitumor action of α(1)-adrenoceptor blockers on human bladder, prostate and renal cancer cells.
Topics: Adrenergic alpha-1 Receptor Antagonists; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Hum | 2012 |
Identification of apoptotic and antiangiogenic activities of terazosin in human prostate cancer and endothelial cells.
Topics: Adenocarcinoma; Animals; Apoptosis; Endothelium, Vascular; Humans; Male; Mice; Mice, Nude; Neovascul | 2003 |
Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Anoikis; Cell Adhesion; Cell | 2003 |
Alpha1-adrenergic receptors activate Ca(2+)-permeable cationic channels in prostate cancer epithelial cells.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Blotting, Western; Boron Comp | 2003 |
Growth inhibiting effects of terazosin on androgen-independent prostate cancer cell lines.
Topics: Adrenergic alpha-Antagonists; Antineoplastic Agents; Cell Division; Cell Line; Humans; Male; Prazosi | 2003 |
Herbal and vitamin supplement use in a prostate cancer screening population.
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Adult; Aged; Colorado; Complementary Therapies; Dietar | 2004 |
[The growth inhibition effect of alpha-adrenoceptor antagonists on androgen- independent prostate cancer cell line].
Topics: Adrenergic alpha-Antagonists; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; Do | 2004 |
Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Anti | 2007 |
Prazosin displays anticancer activity against human prostate cancers: targeting DNA and cell cycle.
Topics: Adrenergic alpha-Antagonists; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Caspases | 2007 |
The alpha-adrenergic blocking effect of prazosin on the human prostate.
Topics: Adenoma; Adrenergic alpha-Antagonists; Humans; Male; Muscle Contraction; Prazosin; Prostate; Prostat | 1981 |
Men's health issues.
Topics: Adrenergic alpha-Antagonists; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Prostatic | 1993 |
Alfuzosin, a selective alpha 1-adrenoceptor antagonist in the lower urinary tract.
Topics: Adenofibroma; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Cats; Decerebrate State; | 1993 |
Identification of alpha 1-adrenoceptor subtypes present in the human prostate.
Topics: Adenoma; Amino Acid Sequence; Animals; Base Sequence; Blotting, Northern; Brain; Cattle; Cell Membra | 1994 |
Characterization and localization of prostatic alpha 1 adrenoceptors using radioligand receptor binding on slide-mounted tissue section.
Topics: Autoradiography; Binding Sites; Humans; Male; Prazosin; Prostate; Prostatic Neoplasms; Radioligand A | 1993 |
[Effects of norepinephrine and alpha-1 adrenergic blockers on cultured stromal cell from benign prostatic hyperplasia].
Topics: Aged; Cell Division; Cell Size; Flow Cytometry; Humans; Male; Middle Aged; Norepinephrine; Prazosin; | 1993 |
Efficacy of selective alpha-1 blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Huma | 1999 |
Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Antagonists; Animals; Antineoplastic Agents; | 2000 |
Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Biopsy; Cell Divis | 2000 |
Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Apoptosis; Cell Division; Endothelial Growth | 2001 |
Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Dose-Response Rela | 2002 |
[Minipress in the treatment of prostatic adenoma].
Topics: Adenoma; Aged; Humans; Male; Middle Aged; Prazosin; Prostatic Neoplasms | 1992 |
[Comparison of selective alpha-1 blockades for alpha-receptors in human hypertrophied prostatic adenomas].
Topics: Adenoma; Adrenergic alpha-Antagonists; Aged; Humans; Male; Piperazines; Prazosin; Prostatic Hyperpla | 1992 |
[Quantitative analyses of human prostatic alpha-adrenoceptors and effects of terazosin on the alpha-adrenoceptor activity].
Topics: Adenoma; Adrenergic alpha-Antagonists; Aged; Humans; Male; Muscle Contraction; Muscle, Smooth; Norep | 1991 |
Binding and functional properties of doxazosin in the human prostate adenoma and canine brain.
Topics: Adenoma; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Brain; Dogs; Doxazosin; Humans | 1990 |
The effects of the alpha 1-adrenergic antagonists terazosin and phentolamine on prostatic adenoma and urethra in vitro.
Topics: Adenoma; Adrenergic alpha-Antagonists; Humans; In Vitro Techniques; Male; Muscle Contraction; Phento | 1989 |